Resurrection of sildenafil: potential for Huntington's Disease, too?
Huntington’s disease
Neurodegeneration
Phosphodiesterase-inhibitor
Sildenafil
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
03
03
2022
accepted:
15
05
2022
revised:
12
05
2022
pubmed:
29
5
2022
medline:
12
8
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
The phosphodiesterase-5 inhibitor sildenafil was postulated to reduce the risk for Alzheimer's Disease. Since preclinical data revealed beneficial effects in Huntington's Disease (HD), we now for the first time investigated effects of sildenafil in HD patients using the database ENROLL-HD. We demonstrate beneficial effects on motoric, functional and cognitive capacities in cross-sectional data. Those effects were not explained by underlying fundamental molecular genetic or demographic data. It remains unsolved, if effects are due to behavioral differences or due to direct dose-dependent neurobiological modulations.
Identifiants
pubmed: 35633374
doi: 10.1007/s00415-022-11196-7
pii: 10.1007/s00415-022-11196-7
pmc: PMC9363275
doi:
Substances chimiques
Sildenafil Citrate
BW9B0ZE037
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5144-5150Informations de copyright
© 2022. The Author(s).
Références
Fang J, Zhang P, Zhou Y et al (2021) Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease. Nat Aging. https://doi.org/10.1038/s43587-021-00138-z
doi: 10.1038/s43587-021-00138-z
pubmed: 35572351
pmcid: 9097949
Walker FO (2007) Huntington’s disease. Lancet 369:218–228. https://doi.org/10.1016/S0140-6736(07)60111-1
doi: 10.1016/S0140-6736(07)60111-1
pubmed: 17240289
Roos RAC (2010) Huntington’s disease: a clinical review. Orphanet J Rare Dis 5:40. https://doi.org/10.1186/1750-1172-5-40
doi: 10.1186/1750-1172-5-40
pubmed: 21171977
pmcid: 3022767
Komatsu H (2021) Innovative Therapeutic approaches for Huntington’s disease: from nucleic acids to GPCR-targeting small molecules. Front Cell Neurosci 15:785703. https://doi.org/10.3389/fncel.2021.785703
doi: 10.3389/fncel.2021.785703
pubmed: 34899193
pmcid: 8662694
Wild EJ, Tabrizi SJ (2019) One decade ago, one decade ahead in Huntington’s disease. Mov Disord 34:1434–1439. https://doi.org/10.1002/mds.27849
doi: 10.1002/mds.27849
pubmed: 31769087
Nabavi SM, Talarek S, Listos J et al (2019) Phosphodiesterase inhibitors say NO to Alzheimer’s disease. Food Chem Toxicol 134:110822. https://doi.org/10.1016/j.fct.2019.110822
doi: 10.1016/j.fct.2019.110822
pubmed: 31536753
Liu L, Xu H, Ding S et al (2019) Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer’s disease. Brain Res Bull 153:223–231. https://doi.org/10.1016/j.brainresbull.2019.09.001
doi: 10.1016/j.brainresbull.2019.09.001
pubmed: 31493542
Sanders O, Rajagopal L (2020) Phosphodiesterase inhibitors for Alzheimer’s disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimers Dis Rep 4:185–215. https://doi.org/10.3233/ADR-200191
doi: 10.3233/ADR-200191
pubmed: 32715279
pmcid: 7369141
Ibrahim MA, Haleem M, AbdelWahab SA et al (2021) Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats. Hum Exp Toxicol 40:596–607. https://doi.org/10.1177/0960327120960775
doi: 10.1177/0960327120960775
pubmed: 32959702
Saavedra A, Giralt A, Arumí H et al (2013) Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington’s disease. PLoS ONE 8:e73664. https://doi.org/10.1371/journal.pone.0073664
doi: 10.1371/journal.pone.0073664
pubmed: 24040016
pmcid: 3764028
Fusco FR, Paldino E (2017) Role of Phosphodiesterases in Huntington’s Disease. Adv Neurobiol 17:285–304. https://doi.org/10.1007/978-3-319-58811-7_11
doi: 10.1007/978-3-319-58811-7_11
pubmed: 28956337
Thakur T, Sharma S, Kumar K et al (2013) Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioral and biochemical toxicities in rats. Eur J Pharmacol 714:515–521. https://doi.org/10.1016/j.ejphar.2013.06.035
doi: 10.1016/j.ejphar.2013.06.035
pubmed: 23831390
Puerta E, Hervias I, Barros-Miñones L et al (2010) Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 38:237–245. https://doi.org/10.1016/j.nbd.2010.01.013
doi: 10.1016/j.nbd.2010.01.013
pubmed: 20109548
Winder JY, Achterberg WP, Gardiner SL et al (2019) Longitudinal assessment of the Unified Huntington’s Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington’s disease. Eur J Neurol 26:780–785. https://doi.org/10.1111/ene.13889
doi: 10.1111/ene.13889
pubmed: 30576046
Ribaudo G, Ongaro A, Zagotto G et al (2020) Therapeutic potential of phosphodiesterase inhibitors against neurodegeneration: the perspective of the medicinal chemist. ACS Chem Neurosci 11:1726–1739. https://doi.org/10.1021/acschemneuro.0c00244
doi: 10.1021/acschemneuro.0c00244
pubmed: 32401481
Tipton PW (2020) Sexual dysfunction in Huntington’s disease: what do we really know? Neurol Neurochir Pol 54:291–293. https://doi.org/10.5603/PJNNS.2020.0034
doi: 10.5603/PJNNS.2020.0034
pubmed: 32870497
Picillo M, Palladino R, Erro R et al (2019) The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson’s disease. Eur J Neurol 26:1327–1333. https://doi.org/10.1111/ene.13983
doi: 10.1111/ene.13983
pubmed: 31267621
Achenbach J, Saft C, Faissner S (2021) Longitudinal evaluation of the effect of tricyclic antidepressants and neuroleptics on the course of Huntington’s disease—data from a real world cohort. Brain Sci 11:413. https://doi.org/10.3390/brainsci11040413
doi: 10.3390/brainsci11040413
pubmed: 33805940
pmcid: 8064332
Achenbach J, Saft C (2021) Data from ENROLL-HD: is the prevalence of juvenile and pediatric Huntington’s disease overestimated? Parkinsonism Relat Disord 88:1–2. https://doi.org/10.1016/j.parkreldis.2021.05.012
doi: 10.1016/j.parkreldis.2021.05.012
pubmed: 34049236